Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

metastatic hormone-sensitive prostate cancer

- PMLiVE

GSK and CureVac look to develop next-generation mRNA COVID-19 vaccines

Novel mRNA vaccines will seek to combat newly emerging variants

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

Bayer symbol

Bayer’s finerenone scores FDA priority review for chronic kidney disease

FDA priority review is based on data from the phase 3 FIDELIO-DKD trial

- PMLiVE

UK approves Moderna’s COVID-19 vaccine, secures another 10 million doses

Total number of doses secured by UK now totals 17 million

- PMLiVE

CureVac and Bayer partner on mRNA-based COVID-19 vaccine

German pharma giant will support further development of CVnCoV

- PMLiVE

First person in the UK given AstraZeneca/Oxford University COVID-19 vaccine

The vaccine can be stored at standard refrigerator temperatures

- PMLiVE

UK regulator warns of allergic reactions to Pfizer/BioNTech vaccine

New MHRA guidance comes after reports of allergic reactions to COVID-19 vaccine

- PMLiVE

NIAID chief back-pedals on criticism of UK’s Pfizer vaccine approval process

Anthony Fauci apologised for previous comments in BBC interview

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine gets first approval from UK

The UK has already signed a supply deal for 40 million doses

- PMLiVE

UK could approve Pfizer’s COVID-19 vaccine this week

The Telegraph reported the possible timeframe on Sunday

AstraZeneca AZ

AZ confirms the UK’s MHRA has started rolling review of its COVID-19 vaccine

Regulatory agency will review data as and when it becomes available

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links